Geron GERN Liability related to sale of future royalties
Liability related to sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Geron in its filing.
Tagged under the XBRL concept gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent.
The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Geron's liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Geron's liability related to sale of future royalties?
- Geron (GERN) reported liability related to sale of future royalties of $19.39M in Q1 2026.
- How has Geron's liability related to sale of future royalties changed year-over-year?
- Geron's liability related to sale of future royalties increased by 24.8% year-over-year, from $15.53M to $19.39M.
- What does liability related to sale of future royalties mean?
- This represents the portion of obligations arising from the monetization of future royalty streams that is due within the next twelve months. It reflects a financing arrangement where the company receives upfront capital in exchange for a portion of future drug revenue. This liability highlights the company's reliance on alternative financing to fund ongoing research and development activities.